Source: Markets Insider

Loxo Oncology: Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

INDIANAPOLIS, Oct. 7, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today an...

Read full article »
Loxo Oncology's Competitors | Loxo Oncology's News | Loxo Oncology's Financials
Stay up-to-date with the latest news on Loxo Oncology
Est. Annual Revenue
$100-500M
Est. Employees
500-1.0K
Jacob S. Van Naarden's photo - CEO of Loxo Oncology

CEO

Jacob S. Van Naarden

CEO Approval Rating

82/100

Read more
Stay up-to-date with the latest news on Loxo Oncology